66324
document
[ Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma . ( Second report ) : 5-year survival rate . Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy ] . In order to examine the efficacy of adjuvant chemotherapy employing mitomycin C ( MMC ) and carmofur ( HCFU ) for patients with noncuratively resected colorectal carcinoma , a cooperative study was performed by 54 institutions in the Kyushu and Chugoku areas of Japan . The criteria for patient selection were as follows : 1 ) Age of 75 years or less and not accompanied by any serious disease . 2 ) Macroscopic diagnosis as being noncuratively resected on completion of the surgical procedure . 3 ) Definitive diagnosis of colorectal carcinomas , histologically . 4 ) No synchronous or metachronous double cancer . The prospective randomized controlled study consisted of two groups . In Group A , the MMC group received bolus intravenous injections of 20 mg MMC on the day of operation and 10 mg the next day , followed by 10 mg every 4 weeks until a total of 100 mg had been administered . In Group B , the MMC + HCFU group received the same treatment in Group A , but with the addition of 600 mg/day of HCFU from the second week , orally for at least one year . Concerning the 69-month survival rate , a better result was observed in the MMC + HCFU group than in the MMC only group ( generalized Wilcoxon test : p less than 0.05 ) . Significantly better survival rates were obtained in those cases with disseminating peritoneal metastasis , hepatic metastasis and stage V cancer in the MMC + HCFU group as when compared with the MMC only group . No significant side effects due to the combined administration of HCFU were recognized . The combined administration of MMC and HCFU was suggested to be a safe and effective adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma .
66325
Intervention_Pharmacological
[ Mitomycin C plus HCFU
66326
Intervention_Pharmacological
adjuvant chemotherapy
66327
Intervention_Pharmacological
mitomycin C ( MMC )
66328
Intervention_Pharmacological
carmofur ( HCFU )
66329
Intervention_Pharmacological
MMC
66330
Intervention_Pharmacological
MMC
66331
Intervention_Pharmacological
MMC + HCFU group
66332
Intervention_Pharmacological
HCFU
66333
Intervention_Pharmacological
MMC + HCFU
66334
Intervention_Pharmacological
MMC + HCFU
66335
Intervention_Pharmacological
HCFU
66336
Intervention_Pharmacological
MMC
66337
Intervention_Pharmacological
HCFU
66338
Outcome_Mortality
69-month survival rate
66339
Outcome_Mortality
survival rates
66340
Outcome_Adverse-effects
significant side effects
66341
Participant_Condition
noncuratively resected colorectal carcinoma
66342
Participant_Sample-size
54
66343
Participant_Condition
institutions in the Kyushu and Chugoku areas of Japan
66344
Participant_Age
Age of 75
66345
Participant_Condition
colorectal carcinomas